Bloomberg TV to air segment on Antigen Express' immunotherapeutic breast cancer vaccine

Generex Biotechnology Corporation (OTCBB:GNBT.OB) today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.  The segment is scheduled to air at 6 pm EST (3 pm PST) today, Monday, December 19, 2011 (see promo at http://i879.photobucket.com/albums/ab357/tc2000chartreader/72389a92.mp4.  It is expected that, once aired, the segment will be available for viewing on the Bloomberg website and on the Generex website.

The story will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in patients with HER-2 expressing breast cancer.  The segment will be featured in Bloomberg's "Innovators" segment, which focuses on world-changing technologies and innovations.

The segment will include an interview by Bloomberg reporter Cali Carlin of Dr. Eric von Hofe, Ph.D., President of Antigen Express, and COL George E. Peoples, MD, FACS, Director, Cancer Vaccine Development Program.

Antigen Express has pioneered technology for increasing the potency of therapeutic anti-cancer vaccines.  Initial clinical studies showed that its lead compound, AE37, indeed showed surprisingly potent immunological activity without sacrificing any specificity in the immune response.  For the last four years, AE37 has been in a controlled, randomized Phase II study to determine whether it can indeed prevent recurrences in patients who have had breast cancer.  Positive interim results from that study were recently presented at the 34^th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).  Final Phase 2 results are expected in 2012.

The Antigen Express AE37 breast cancer vaccine was also featured in Newsweek magazine on December 12, 2011 in science columnist and science editor Sharon Begley's article, Could This Be The End of Cancer?:(http://www.thedailybeast.com/newsweek/2011/12/11/could-this-be-the-end-of-cancer.html)." 

SOURCE Generex Biotechnology Corporation